Apoptotic cell death and its relationship to gastric carcinogenesis by Bir, Ferda et al.
bcl-2 positivity compared to intestinal metaplasia areas 
adjacent to chronic gastritis [55.5% (15/27) vs  70.5% 
(12/17), respectively]. On the other hand, intestinal 
metaplasia areas adjacent to tumors showed significantly 
higher cytoplasmic bax positivity compared to intestinal 
metaplasia areas adjacent to chronic gastritis [44.4% 
(12/27) vs  11.7% (2/17), respectively; P ≤ 0.05].
CONCLUSION:  Existence of apoptotic cells on the basis 
of TUNEL positivity is shown in intestinal metaplasias 
co-localizing to both diffuse and intestinal type gastric 
cancers in this study. Our results also suggested bax 
expression dependent induction of apoptosis especially 
in intestinal metaplasia areas adjacent to tumors. These 
findings strongly support the involvement of apoptotic 
mechanisms in the process of gastric carcinogenesis 
especially in the transition from intestinal metaplasia 
to gastric cancer. It may be suggested that induction 
of apoptosis in intestinal metaplasia areas adjacent to 
tumors may involve different mechanisms than induction 
by chronic inflammation.
© 2007 The WJG Press. All rights reserved.
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INTRODUCTION
Studies by Correa have suggested that development of  
gastric cancer is a multistep process involving a series 
of  events such as atrophic gastritis, intestinal metaplasia, 
and dysplasia. According to this model, these lesions are 
considered to be precancerous[1].
The cellular turnover of  the gastric tissue and the 
balance within this unstable tissue is maintained by the 
processes known as proliferation and apoptotic cell 
death[2,3]. However, the apoptotic cell death plays an 
important role in the regulation of  pathological conditions 
as well, such as development and progression of  malignant 
tumors[3,4]. Among the methods that are used to identify 
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Abstract
AIM: To investigate the apoptotic process of cells 
within the intestinal metaplasia areas co-localizing with 
chronic gastritis and gastric carcinomas and to analyze 
the involvement of proteins regulating apoptosis in 
the process of intestinal metaplasia related gastric 
carcinogenesis.
METHODS: Forty-two gastric carcinoma and seventeen 
chronic gastritis cases were included in this study. All 
cases were examined for the existence of intestinal 
metaplasia. Ten cases randomly selected from each 
group were processed for TUNEL assay. TUNEL 
positive cells within the intestinal metaplasia areas, co-
localizing either to gastric carcinoma or chronic gastritis, 
were counted and converted to apoptotic indices. 
In addition, p53, bcl-2 and bax expression patterns 
within these tissues were analyzed on the basis of 
immunohistochemistry. 
RESULTS: Twenty-eight of the cases were intestinal 
and 14 of the cases were diffuse type adenocarcinomas. 
64% (27/42) of the gastric carcinoma cases had 
intestinal metaplasia. Intestinal metaplasia co-localized 
more with intestinal type carcinomas compared with 
diffuse type carcinomas [75% (21/28) vs  42% (6/14), 
respectively; P ≤ 0.05]. The mean apoptotic index in 
tumor cells was 0.70 ± 0.08. The mean apoptotic index 
in intestinal metaplasias co-localizing to tumors was 
significantly higher than that of intestinal metaplasias 
co-localizing to chronic gastritis (0.70 ± 0.03 vs  0.09 
± 0.01, respectively; P ≤ 0.05). p53 positivity was not 
observed in areas of intestinal metaplasia adjacent 
to tumors or chronic gastritis. Intestinal metaplasia 
areas adjacent to tumors showed lower cytoplasmic 
PO Box 2345, Beijing 100023, China                                                                                                                      World J Gastroenterol  2007 June 21; 13(23): 3183-3188
www.wjgnet.com                                                                                                                                          World Journal of Gastroenterology  ISSN 1007-9327
wjg@wjgnet.com                                                                                                                                                                       © 2007 The WJG Press. All rights reserved.
www.wjgnet.com
cells undergoing the apoptotic process, the TUNEL 
technique is one of  the most successfully utilized[4]. 
Gastric epithelium is exposed to damaging agents 
in nature[2]. These agents may result in DNA damage in 
these epithelial cells. In response to DNA damage and 
other stress, p53 is activated by several post transcriptional 
modifications, which in turn activates its down-stream 
targets to induce cell cycle arrest or apoptosis. An arrested 
cell cycle allows the repair of  the DNA damage. However, 
failure of  the repair of  the DNA damage results in 
activation of  apoptosis by p53. Thus, p53 has a major 
tumor suppressor role in this process and mutations that 
abolish p53 function may fail to control this mechanism[5] 
and induce excessive cell proliferation and/or decreased 
cell apoptosis, which seem to be the biological basis of  
gastric carcinogenesis[3]. 
Bcl-2 family proteins are important apoptotic regulators 
and can act either pro- or anti-apoptotically. The bcl-2 
gene product codes for anti-apoptotic protein, whereas the 
bax and bad gene products act pro-apoptotically. p53 has 
also been suggested for deregulation of  cell death through 
Bax-Bcl-2 imbalances[5].  
Intestinal metaplasia has been extensively studied 
as a possible premalignant condition in the human 
stomach[1,6-8]. Moreover, many questions remain regarding 
pathogenesis of  intestinal metaplasia development as well 
as its relationship to gastric cancer. In this study, we have 
investigated immunohistochemical expression of  apoptosis 
related proteins p53, bax and bcl-2 and TUNEL staining in 
the areas of  intestinal metaplasia adjacent to gastric cancer 
and chronic gastritis in order to determine the apoptotic 
bodies to understand their role in gastric carcinogenesis. 
MATERIALS AND METHODS
Paraffin-embedded biopsies or surgical specimens from 42 
cases with gastric carcinomas and 17 cases with intestinal 
metaplasia and chronic atrophic gastritis were assessed in 
the Pamukkale University School of  Medicine Department 
of  Pathology (Figure 1A and B). Clinical characteristics 
of  these patients were described in Table 1. Histological 
diagnoses and classification of  tumors were based on 
Lauren’s criteria[9] and intestinal metaplasia, chronic 
atrophic gastritis were diagnosed according to the updated 
Sydney system[10]. Intestinal metaplasias were classified 
according to Filipe et al[11]. 
Immunohistochemistry 
Sections from each representative specimen were cut at 
3-5 μm, mounted on glass and dried overnight at 37℃. 
Briefly, all sections were then deparaffinized in xylene, 
dehydrated through a graded series of  alcohol and washed 
in distillated water. Distillated water was used for all 
subsequent washes and dilution of  the antibodies. Tissue 
sections were heated twice in a microwave oven for 10 min 
each at 700 W in citrate buffer pH 6 and then processed 
with the standard streptavidin-biotin-immunoperoxidase 
method with automatically Ventana-Nexes immunostainer 
(Ventana Medical Systems, Tucson, Arizona). Monoclonal 
mouse anti-human p53 protein antibody (Clone DO-7, 
Neomarkers, Inc. 47790 Westinghouse Dr., Fremont CA 
94539, USA) at a 1/50 dilution, monoclonal mouse anti-
human antibody anti-Bcl-2 (Clone 7D9, Neomarkers, 
Inc. 47790 Westinghouse Dr., Fremont CA 94539, USA) 
at a 1/50 dilution, rabbit polyclonal immune serum 
raised against bax (Clone 2D2, Neomarkers, Inc. 47790 
Westinghouse Dr., Fremont CA 94539, USA) at a 1/20 
dilution were used. Diaminobenzidine was used as the 
final chromogen, and Mayer’s haematoxylin as the nuclear 
counter stain. 
Sections were evaluated for the staining of  p53, 
bcl-2 and bax proteins semi quantitatively. The protein 
expression in each specimen is scored for the percentage 
of  positive neoplastic cells and intestinal metaplasia cells: 
score 0 = undetectable staining or < 20% of  positive cells; 
score 1 = ≥ 20 positive cells. Nuclear staining for p53 
and cytoplasmic staining for bax and bcl-2 were scored. 
Lymphocytes and small vessels were used as positive 
controls for bcl-2 and bax immunoreactivity, respectively.
Detection of apoptosis
Apoptotic activity was analyzed on the basis of  terminal 
deoxynucleotidyl transferase (TdT)-mediated deoxyuridine 
triphosphate (dUTP) nick end labeling (TUNEL) assay.  
Sections from the same blocks of  selected cases were cut 
at 10 μm, and mounted on glass. These sections were   
processed with the In Situ Cell Death Detection Kit, AP 
(Roche, Penzberg, Germany) according to the manufac-
turer’s protocol for paraffin-embedded tissues. BM Purple 
AP Substrate, precipitating (Roche, Penzberg, Germany) 
chromogenic substrate was used for alkaline phosphatase 
enzyme immunoassay at the last step. We sought positive   
TUNEL staining against background of  nuclear staining 
of  gastric cancer and intestinal metaplasia cells.
Statistical analysis
SPSS software (version 10.00) was used for statistical 
analysis. Pearson’s Chi-square test or Fisher’s exact test 
were applied to analyze the data when appropriate. 
TUNEL staining results were statistically evaluated 
using the test for difference between two population 
proportions. P < 0.05 was taken as statistically significant. 
RESULTS
Gastric carcinoma cases were assessed according to 
Lauren’s classification and 28 intestinal, 14 diffuse type 
adenocarcinomas were included in this study. Intestinal 
Table 1  Clinical characteristics of cases
Intestinal 
metaplasia (n )
Sex (n)
Female Male
Age of 
cases (mean)
Number of 
cases (n )
Chronic gastritis 17   7           10 53.6 ± 16.0 17
Intestinal type 
adenocarcinoma
21 10           18 63.2 ± 10.3 28
Diffuse type   
adenocarcinoma
  6   7            7 57.4 ± 16.6 14
Adenocarcinoma 27 23          19 53.5 ± 12.8 42
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metaplasia was observed in 75% (21/28) of  intestinal type 
carcinoma cases, 42% (6/14) of  diffuse type carcinoma 
cases and 64% (27/42) of  the overall gastric carcinoma 
cases (Figure 2A and B). Intestinal metaplasia areas 
were co-localized more with intestinal type carcinomas 
compared with diffuse type carcinomas and the difference 
was stat ist ical ly s ignif icant (P ≤ 0.05). Intestinal 
metaplasias co-localizing to tumors were classified 
according to Filipe and are shown to be 93% (25/27) Type
Ⅰ, and 8% (2/27) Type Ⅱ; on the other hand, intestinal 
metaplasias co-localizing to chronic gastritis were all TypeⅠ.
Randomly selected cases of  tumor with adjacent 
intestinal metaplasia and ten cases of  chronic gastritis 
with adjacent intestinal metaplasia were stained by the 
TUNEL method for the determination of  apoptotic 
nuclei. Variable numbers of  tumor cells were shown to 
have apoptotic nuclei in all of  the tumor cases. Especially 
intestinal type gastric carcinoma cells showed abundant 
positivity compared to  diffuse type. Also some of  the 
intestinal metaplastic cells adjacent to all of  the gastric 
carcinoma showed positivity for TUNEL staining (Figure 
2C). The mean apoptotic index in tumor cells was 0.70 ± 
0.08, in intestinal metaplasias co-localizing to tumors it 
was 0.70 ± 0.03, and in intestinal metaplasias co-localizing 
to chronic gastritis was 0.09 ± 0.01 (Figures 1C and 2C). 
The difference between the mean apoptotic indexes in 
Figure 1  A: Chronic gastritis with intestinal 
metaplasia (HE, x 10); B: Areas of intestinal 
metaplasia in chronic gastritis (HE, x 40); C: 
A few intestinal metaplastic cells adjacent 
to the chronic gastritis showed positivity for 
TUNEL staining; D: Intestinal metaplasia 
areas adjacent to chronic gastritis without 
cytoplasmic bax positivity.
A B
C D
A B
C D
Figure 2  A: Adenocarcinoma with intestinal 
metaplasia (HE, x 10); B: Areas of intestinal 
metaplasia in adenocarcinoma (HE, x 40); C: 
Abundant intestinal metaplastic cells adjacent 
to the adenocarcinoma showed positivity 
for TUNEL staining; D: Intestinal metaplasia 
areas adjacent to adenocarcinoma with 
strong cytoplasmic bax positivity.
www.wjgnet.com
Bir F et al.  p53, apoptosis and related proteins in intestinal metaplasia                                                    3185
intestinal metaplasias co-localizing to tumors and chronic 
gastritis was statistically significant (P ≤ 0.05) (Table 2). 
Immunohistochemically tumor cells were nuclear 
positive for p53 in 57.1% (24/42), cytoplasmic positive for 
bcl-2 in 47.6% (20/42) and again cytoplasmic positive for 
bax in 42.8% (18/42) in gastric carcinoma cases. There was 
no nuclear p53 positivity in areas of  intestinal metaplasia 
adjacent to tumors or chronic gastrit is. Intestinal 
metaplasia areas adjacent to tumors showed 55.5% (15/27) 
cytoplasmic bcl-2 positivity, whereas intestinal metaplasia 
areas adjacent to chronic gastr i t is showed 70.5% 
(12/17) cytoplasmic bcl-2 positivity (Table 2). Intestinal 
metaplasia areas adjacent to tumors showed 44.4% (12/27) 
cytoplasmic bax positivity, whereas intestinal metaplasia 
areas adjacent to chronic gastritis showed 11.7% (2/17) 
cytoplasmic bax positivity (Figures 1D and 2D). The 
difference in this comparison was statistically significant 
(P ≤ 0.05) (Table 2).
DISCUSSION
This study demonstrated that TUNEL positivity of  
cells within the intestinal metaplasia areas adjacent to 
tumors is significantly higher than that of  cells within the 
intestinal metaplasia areas adjacent to chronic gastritis. 
In addition, a significant increase in bax positivity of  
cells within the intestinal metaplasia areas adjacent to 
tumors in comparison to chronic gastritis suggested that 
the induction of  apoptosis within these areas is at least 
partially bax mediated. 
Correa have previously proposed a human model of  
gastric carcinogenesis for intestinal type gastric carcinoma, 
based on epidemiological, pathological, and clinical 
observations. According to this model, gastric carcinoma 
of  the intestinal type originates in dysplastic epithelium, 
which in turn develops in atrophic gastritis followed by 
intestinal metaplasia. Experiments in several populations 
at high gastric cancer risk have documented a series of  
lesions, which are inflammation (chronic gastritis), atrophy, 
and loss of  cellular differentiation. In reality the loss of  
differentiation appears to represent successive mutations, 
since the gastric epithelial cells disappear as such and are 
replaced by cells with intestinal phenotype, the daughters 
of  these “mature” intestinal cells then display apparently 
progressive phenotypic changes, lose some of  their 
normal cytoplasmic secretions and gain autonomy, which 
eventually leads to uninhibited replication and invasion 
of  the neighboring tissues[1,11]. According to Correa, 
the normal gastric cells are replaced by cells expressing 
mature intestinal phenotype in the process of  gastric 
carcinogenesis in humans and these are then replaced by 
cells with immature phenotypes capable of  synthesizing 
the same cytoplasmic products of  the neck cells. It is 
not clear if  the neck cell acts as a stem cell or if  it is 
derived from a precursor stem cell[1,12]. Supporting these 
suggestions our cases showed increased co-localization 
of  intestinal metaplasia in intestinal type tumors in 
comparison to others.
Several classifications of  intestinal metaplasia have been 
suggested by pathologists.  Different observers proposed 
different definitions and criteria for classification[13]: Small 
intestine/colonic type[14,15], complete/incomplete type[16,17] 
and typeⅠcorresponds to the complete and types Ⅱ and 
Ⅲ to the incomplete type[18]. These classifications are 
based on only the intestinal properties. Recently a new 
classification was proposed based upon both gastric and 
intestinal differentiation status[13]: a gastric and intestinal 
mixed type, and solely intestinal type. In general intestinal 
metaplasia especially type Ⅲ-colonic metaplasia is 
suggested as a preneoplastic lesion in these classifications
[1,19-21]. However, there are studies that do not support this 
hypothesis even for colonic type intestinal metaplasias[22]. 
Supporting this last idea, this study showed intestinal 
metaplasia areas co-localizing to both intestinal and diffuse 
type cancers. Although, the incomplete type of  intestinal 
metaplastic is more commonly associated with an increased 
risk of  malignant transformation[1,3,11], this study showed 
co-localization of  type-I metaplasia to all chronic gastritis 
cases and in almost all, i.e., in all except 2, tumor cases. 
Those 2 tumor cases showed type-Ⅱ intestinal metaplasia 
co-localizing to tumors.  
Studies investigating small gastric cancers showed 
that atrophy and dysplasia do not always co-localize with 
early neoplasia suggesting that metaplasia is not a definite 
preneoplastic lesion[23,24]. In addition, histogenesis studies 
of  gastric cancers suggest that the majority of  both diffuse 
and intestinal gastric cancers develop from non-metaplastic 
stem cells. It is believed that in these cases first gastric 
phenotype develops and intestinal phenotype is secondary 
to gastric phenotype. Thus, gastric cancer cells show 
heterogeneity in terms of  gastric and intestinal phenotypic 
markers. However, it is not clear whether they consist of  
different types of  cells or are derived from multipotential 
cells. All these findings suggest that the type of  intestinal 
metaplasia is not directly important in the process of  
gastric cancer development[13].
Few s tud ies inves t ig a t ing g as t r i c cancer and 
involvement of  apoptosis in this condition have shown 
the existence of  apoptotic cells within the normal gastric 
mucosa, intestinalized glands, adenomatous dysplasia 
and carcinomas[25,26]. The involvement of  proliferation 
and apoptosis in the transition from normal mucosa 
to atrophic gastritis and intestinal metaplasia has been 
studied especially in relation to HP related gastric 
carcinogenesis[26,27]. In normal gastric mucosa TUNEL 
Table 2  Results of TUNEL staining and immunohistochemical 
data
Chronic gastritis
co-localization of 
intestinal metaplasia
Adenocarcinoma  
co-localization of 
intestinal metaplasia
P
TUNEL (mean) 0.09 ± 0.01 0.70 ± 0.03 ≤ 0.05
p53
-   Positive   0   0
   Negative 17 27
BCL-2
> 0.05   Positive 12 15
   Negative   5 12
BAX
≤ 0.05   Positive   2 12
   Negative 15 15
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positive cells are abundant in foveolar epithelium, whereas 
in chronic gastritis this finding is accompanied by increased 
cell proliferation. In intestinal metaplasias adjacent to 
chronic gastritis, on the other hand, proliferation rate 
shows an increase whereas apoptotic index does not 
change significantly[26]. Findings of  this study also support 
this last observation. However, TUNEL positivity 
in intestinal metaplasia areas adjacent to tumors was 
significantly higher than that of  normal mucosa adjacent 
to tumors and to intestinal metaplasia adjacent to chronic 
gastritis. 
Many in vivo and in vitro studies have also investigated 
the apoptotic process in gastric carcinomas and its relation 
to the p53 gene[28-31]. Findings from these studies are also 
in concordance with findings from this study in terms 
of  observation of  more apoptotic cells in intestinal type 
carcinomas in comparison to diffuse type carcinomas[4,25,28]. 
In one of  these studies Ikeda et al[25] investigated TUNEL 
positivity based apoptotic index, ki-67 index and p53 
expression in a series of  minute, early and late stage gastric 
carcinomas. On the basis of  well and poorly differentiated 
carcinoma classification they found asignificant increase 
in apoptotic and proliferating cells in well differentiated 
carcinomas in comparison to poorly differentiated 
carcinomas. However, p53 expression did not show any 
significant difference between minute, early and late stage 
gastric carcinomas. Based on these findings they suggested 
that gastric cancer development involves increased 
proliferation together with apoptotic mechanisms induced 
independently of  p53 expression. However, there are 
also studies opposing this hypothesis[29,30,31]. Studies 
suggesting intestinal metaplasia as preneoplastic lesion 
have reported 30% p53 mutations especially in incomplete 
type metaplasias. p53 protein accumulation in gastric 
carcinogenesis, on the other hand, is first seen at the 
dysplasia stage[31]. Analysis of  p53 expression in intestinal 
metaplasia areas adjacent to both gastric cancers and 
chronic gastritis on the basis of  immunohistochemistry 
did not reveal any p53 protein accumulation in this study.
I t has been shown that upregulat ion of  bcl -2 
expression in premalignant lesions is followed by its down 
regulation after malignant differentiation[31,32]. Analysis 
of  bcl-2 expression in intestinal metaplasia areas adjacent 
to both gastric cancers and chronic gastritis on the basis 
of  immunohistochemistry did not reveal any significant 
difference in this study. However, the comparison of  bax 
expression between these two groups revealed increased 
bax expression in intestinal metaplasia areas adjacent to 
gastric cancer. The literature search revealed only a few 
studies, in which the investigators analyzed the expression 
patterns of  apoptosis related proteins and their relation to 
preneoplastic lesions in gastric carcinoma[33-35]. However, 
none of  these studies have investigated the relationship 
between the expression patterns of  these apoptosis related 
proteins in intestinal metaplasia areas co-localizing to 
tumors. In this study, in addition to the above mentioned 
relationship the expression patterns of  the apoptosis 
related proteins in intestinal metaplasia areas co-localizing 
to chronic gastritis was investigated. Finally, these 
expression patterns were compared to each other.
In conclusion, existence of  apoptotic cells on the basis 
of  TUNEL positivity is shown in intestinal metaplasias 
co-localizing to both diffuse and intestinal type gastric 
cancers in this study. Our results also suggested bax 
expression dependent induction of  apoptosis especially 
in intestinal metaplasia areas adjacent to tumors. These 
findings strongly support the involvement of  apoptotic 
mechanisms in the process of  gastric carcinogenesis 
especially in the transition from intestinal metaplasia to 
gastric cancer. Finally, induction of  apoptosis in intestinal 
metaplasia areas adjacent to tumors may involve different 
mechanisms than induction by chronic inflammation.
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